The Future of
Preclinical Drug Testing
Human-Relevant 3D Tissue Models at Scale
Artificell delivers physiologically accurate organ-on-a-chip platforms that revolutionize preclinical testing. Our scaffold-free 3D tissue models provide unprecedented predictive power, reducing clinical trial failures and accelerating drug discovery.
The Clinical Translation Gap
Current preclinical testing approaches are plagued by poor clinical translation
Drug Development Attrition Flow
10,000 compounds → outcomes by scenario
The Attrition Rate
90% of all drug candidates fail during clinical development (Phase I through approval). The primary reasons are a lack of efficacy and unexpected toxicity when tested in humans.
Model Accuracy Issues
<60% predictive accuracy for traditional animal models. Translation success from animal cancer studies to human trials can be as low as 8%, highlighting the limitations of current preclinical methods.
The Economic Toll
$2.6 Billion is the estimated average cost to research and develop a single new prescription drug that receives market approval, including the costs of all failed trials.
How It Works
Microfluidic engineering combined with advanced cell biology to create physiologically relevant tissue models
Cell Seeding
Patient-derived or iPSC cells seeded into scaffold-free microfluidic chambers
3D Culture
Self-organized 3D structures with controlled perfusion and physiological conditions
Real-Time Analysis
Integrated sensors monitoring tissue function, viability, and drug response
Data Output
Comprehensive datasets on efficacy, toxicity, and mechanism of action
Proprietary Advantages
Scaffold-Free Architecture
Cells organize naturally without artificial matrices, preserving native tissue structure
Physiologically Relevant
Precise control of perfusion, oxygen gradients, and mechanical forces mimics in vivo
Scalable & Automated
Automated workflows enable high-throughput screening with batch consistency
Multi-Organ Systems
Model complex drug metabolism and organ-organ interactions on single platform
Fast, Simple, Versatile
From compound screening to advanced imaging—our platform adapts to your research needs
Contracting tissue in microplate well
Functional Compound Screening
Test novel compounds and get functional read-outs like beating force, beating frequency, or tissue tension in real-time with our high-throughput platform.
Powerful Software. Effortless Analysis.
Our intuitive analysis platform transforms complex biological data into actionable insights
Real-Time Analytics
Monitor tissue responses with live data streaming and instant visualization
Automated Reporting
Generate publication-ready graphs and statistics with one click
Multi-Parameter Tracking
Simultaneously measure contractility, viability, and morphology
Data Management
Secure cloud storage with LIMS integration and audit trails
API Access
Integrate with your existing workflows via REST API
ML-Powered Analysis
AI-driven pattern recognition and predictive modeling
Watch Platform Demo
See our software in action with a guided 5-minute walkthrough
Technical Documentation
Download software specs, API docs, and integration guides
MANY INTEGRATES
World-Class Expertise
Pioneers in bioengineering with decades of combined experience from top pharma and academic institutions
Mattias Luber
Background in Data Sciences
Experience TBD
Dr. Arne Hofemeier
Ph.D. Bioengineering, University Medical Center Göttingen
Ex-Regeneron Principal Scientist
Dr. Till Münker
Ph.D. Biophysics, University TBD
Experience TBD
Bruno Schmelz
M.S. Chemistry, University TBD
Experience TBD
Prof. Timo Betz
Ph.D. Biophysics, University TBD
Experience TBD
Scientific Advisory Board
Guided by renowned experts from Harvard Medical School, Johns Hopkins, and leading pharma. Deep expertise in drug development, regulatory affairs, and clinical translation.
Our Partners
Backed by top-tier biotech VCs and strategic industry partners who share our vision of transforming drug discovery through human-relevant tissue models.
Artificell's platform identified cardiotoxicity in three of our lead compounds that passed conventional screening. This early detection saved us millions in development costs and potentially years of wasted effort.
Partner With Artificell
Get customized pricing and solutions tailored to your drug development pipeline
Get Your Custom Quote
Connect with our team to discuss your needs